Eli Lilly has dropped its phase 2 Alzheimer's disease program for mevidalen, marking another setback for the experimental ...

Bristol Myers Squibb has scrapped a phase 1 program it licensed from Prothena for $80 million. | Bristol Myers Squibb has ...

BioMarin is paying $70 million upfront to license a Fabry disease drug candidate, expanding the franchise it acquired through ...

Flagship Pioneering unveiled Etcelera today, a new AI-powered biotech emerging from stealth that aims to predict how potential medicines will act in patients.

Scientists have known for a while that Angelman syndrome is caused by the loss of a specific gene, but they didn't understand ...

At Week 12 of its own phase 1b diabetes study, Lilly reported weight loss of up to 5.8 kg on Foundayo, compared to a 0.5 kg ...

Eli Lilly’s triple-G drug candidate retatrutide has beaten Novo’s Ozempic in a head-to-head phase 3 trial, driving deeper ...

During a public hearing Wednesday to discuss a newly proposed rare disease framework, FDA center director Michael Davis, M.D.

Genmab acquired the immunoglobulin G1 bispecific antibody through its $8 billion acquisition of Merus last year. Petosemtamab binds both epidermal growth factor receptor (EGFR) and leucine-rich repeat ...

GSK’s global restructuring plan is likely to see “some limited impact” on roles in the Big Pharma’s home turf of the U.K., ...

Every ESMO conference is eventful, but the drama kicked into gear earlier than expected this year when the eagerly ...

Chicago-based Syntax Bio believes it has cracked the code for turning stem cells into pancreatic beta cells in as little as ...